Immunization for Streptococcus pneumoniae infections in high-risk children

Carrie L. Byington, Yvonne A. Maldonado, Elizabeth D. Barnett, Herbert Dele Davies, Kathryn M. Edwards, Mary Anne Jackson, Dennis L. Murray, Mobeen H. Rathore, Mark H. Sawyer, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis, Jennifer M. Frantz, Doug Campos-Outcalt, Marc A. Fischer, Bruce G. Gellin, Richard L. Gorman, Lucia H. Lee, R. Douglas Pratt, Joan L. RobinsonMarco Aurelio Palazzi Safadi, Jane F. Seward, Jeffrey R. Starke, Geoffrey R. Simon, Tina Q. Tan

Research output: Contribution to journalShort surveypeer-review

17 Scopus citations


Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.

Original languageEnglish (US)
Pages (from-to)1230-1233
Number of pages4
Issue number6
StatePublished - Dec 1 2014


  • Immunization
  • Invasive pneumococcal disease
  • PCV13
  • PPSV23
  • Pneumococcal vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Immunization for Streptococcus pneumoniae infections in high-risk children'. Together they form a unique fingerprint.

Cite this